MEET TIEFENBACHER GROUP AT BEPHARMA IN MEXICO CITY FROM OCTOBER 10-12!

Reach out to AET – TIEFENBACHER PHARMACEUTICALS at BePharma, the most important Pharma B2B Event in Latin America from October 10-12!  Discover our latest product portfolio in Mexico City…

Read More

NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES GENERIC VERSION OF THE DIABETIS MEDICINE VILDAGLIPTIN AND VILDAGLIPTIN/METFORMIN in AFRICA

We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines available and affordable to as many people as possible around the world. That´s why we are happy to share that…

Read More

Environmentally friendly and health-promoting: TIEFENBACHER GROUP offers bike leasing to employees

From racing bikes to E-bikes: since this year all our employees at our Hamburg headquarters can choose from a broad range of company bikes to lease. A great opportunity for everyone to…

Read More

GLOBAL MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS EXPANDS THE LAUNCH OF THE ANTICOAGULANT MEDICINE RIVAROXABAN TO CENTRAL AMERICA AND FURTHER INTERNATIONAL MARKETS

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be available for all patients around the world – irrespective of their origin or…

Read More

NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE MULTIPLE SCLEROSIS MEDICINE TERIFLUNOMIDE IN CANADA

We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are happy to share that we…

Read More

TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI)

We at TIEFENBACHER GROUP are committed to promote sustainable and responsible business along the whole pharmaceutical supply chain. That’s why we are excited to become a member of PSCI – a…

Read More

TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA

TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for…

Read More

WORLD HEALTH DAY @ TIEFENBACHER GROUP

Today we celebrate World Health Day. In times of a global pandemic and a cruel war in Europe, it is more important than ever that we all work together to create a healthier tomorrow. Since…

Read More

Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!

One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP…

Read More

NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE EPILEPSY MEDICINE LACOSAMIDE IN AUSTRALIA

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their…

Read More

TIEFENBACHER GROUP STANDS WITH UKRAINE

To us at TIEFENBACHER GROUP, it is unbearable to witness what is happening in Ukraine. We condemn the Russian state´s invasion as a brutal act of war against a neighbouring sovereign…

Read More

MEET TIEFENBACHER GROUP DURING DCAT WEEK IN NEW YORK CITY FROM 21-24th MARCH!

Reach out to TIEFENBACHER GROUP at DCAT in New York City from 21-24th March and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!…

Read More

Featured Video Play Icon

TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!

We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three…

Read More

Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities

Did you know that TIEFENBACHER GROUP heavily invests in its own manufacturing facilities to secure an efficient and reliable supply of our high-quality pharmaceuticals for patients around the world?…

Read More

Featured Video Play Icon

Three successful days for TIEFENBACHER GROUP at CPhI 2021 – thanks for visiting us in Milano!

With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma event CPhI has just come to an end. It was three very successful days for TIEFENBACHER GROUP…

Read More

Featured Video Play Icon

At TIEFENBACHER GROUP giving back to society is important to us: New school building in India

As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society –…

Read More

Reach out to TIEFENBACHER GROUP at CPhI in Milan from 9-11th Nov and discover our latest ideas to make pharmaceuticals more affordable, more available and better than before!

“Nothing can replace meeting each other in person!” says Oliver Schrader, Managing Director of Tiefenbacher Group. After nearly two years of mainly digital work, we are very excited to be back on the…

Read More

New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the antihistamine Bilastine

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why we are excited…

Read More

New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP

Swedish Life science company OnDosis and German B2B pharmaceutical company TIEFENBACHER GROUP initiate four new innovative development projects targeting ADHD, rare diseases, and transplantation…

Read More

Spreading of Post COVID-19 Disease „Black Fungus“ in India – TIEFENBACHER GROUP supports with Posaconazole Tablets

Black Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised…

Read More

TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES

After more than five years in operation, TIEFENBACHER GROUP will transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES. The launch follows TIEFENBACHER…

Read More

TIEFENBACHER PHARMACEUTICALS announces global launch of Teriflunomide making multiple sclerosis therapy more affordable and better available worldwide

TIEFENBACHER PHARMACEUTICALS, part of TIEFENBACHER GROUP, has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mg film-coated tablets.   Teriflunomide is an…

Read More

AET Pharma US Inc. Announces Successful approval of generic Posaconazole by the Food and Drug Administration (FDA)

On 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole 100 mg Delayed-Release Tablets. This is…

Read More

TIEFENBACHER PHARMACEUTICALS Announces Global Launch Of Rivaroxaban

TIEFENBACHER PHARMACEUTICALS, part of Tiefenbacher Group, is pleased to announce the availability of a registration dossier for the generic of Rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg film-coated…

Read More

International Brand Relaunch of TIEFENBACHER GROUP

“We are very excited to launch our new AET website, representing the pharmaceutical FDF business of TIEFENBACHER GROUP. It is an important milestone within the international brand relaunch of our…

Read More

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…

Read More